Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX02 vs Herceptin PK and Safety Study in Healthy Chinese Males
NCT02581748Phase 1Completed
- Sponsor
- Henlius
- Start
- Sep 2015
- Primary completion
- May 2016
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of trastuzumab in HER2-positive breast cancer and gastric cancer (GC) (2 cohorts), sponsored by Henlius. Primary endpoint: Area under the concentration-time curve from time zero to infinity at 57 days. Started Sep 2015; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancergastric cancer (GC)
Beyond the preview
Go deeper on NCT02581748.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02581748.